E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (3a) or (E)-3-(4-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (3b) were prepared from reaction of 4-hydroxyacetophenone (1) and 4-chlorobenzaldehyde (2a) or 4-methoxybenzaldehyde (2b), respectively.The reaction of 3a or 3b and various N-aryl-2-chloroacetamides (4a-d) afforded eight new N-aryl-2-(4-(3-(4substituted phenyl)acryloyl)phenoxy)acetamide compounds (5a-h).The structures of the compounds were confirmed by IR, 1 H-NMR, 13 C-NMR and HR-MS spectral data.Antioxidant activity performed by DPPH radical scavenging method showed that N-aryl-2-(4-(3-(4-substituted phenyl)acryloyl)phenoxy)acetamide compounds (5a-h) at a concentration of 10.0 μg/ mL possess antioxidant activity in equivalent to that of ascorbic acid at a concentration of 6.0-8.0 μg/ mL while the antioxidant activity of 3a and 3b compounds is higher that of ascorbic acid at the same concentration.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2021) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: